Form 4: TriSalus Life Sciences Director Transfers Stock Options to Living Trust

Director Andrew von Eschenbach transferred stock options to The Vons Living Trust but remains the beneficial owner.

Summary

• Andrew von Eschenbach, a director of TriSalus Life Sciences, Inc. (TLSI), filed a Form 4 to report changes in beneficial ownership.
• On June 3, 2024, von Eschenbach transferred stock options to The Vons Living Trust U/T/A 4/3/2024 dated 4/3/2024.
• The transfer involved 35,000 stock options with an exercise price of $11.34.
• These options were originally granted with a vesting commencement date of August 10, 2023, and vest in three equal annual installments.
• The expiration date for these options is August 9, 2033.
• Despite the transfer, von Eschenbach remains the beneficial owner of the securities held by the Trust, as he and his spouse are co-trustees, and he is the sole beneficiary.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Form 4) detailing a transfer of stock options to a trust. It doesn't inherently convey positive or negative sentiment regarding the company's performance or future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders, such as directors and officers, in their company's stock. This filing indicates a transfer of stock options to a trust, which is a common estate planning strategy.

Related Party Transactions

• The transfer of stock options to The Vons Living Trust, of which Andrew von Eschenbach is a co-trustee and sole beneficiary, constitutes a related party transaction.

Stakeholder Impact

• The transfer of stock options has minimal direct impact on stakeholders, as von Eschenbach remains the beneficial owner.

Key Dates